HIỆU QUẢ ĐIỀU TRỊ SORAFENIB TRONG UNG THƯ BIỂU MÔ TẾ BÀO GAN GIAI ĐOẠN TIẾN XA

Abstract

Background: Sorafenib - an oral multikinase inhibitor that inhibits tumor-cell proliferation and tumor angiogenesis - has been shown in phase III studies to prolong overall survival. Until recently, sorafenib is considered the standard treatment for patients with advanced hepatocellular carcinoma (HCC). Objective: Evaluate the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and toxicity of sorafenib in advanced HCC. Patients and method: Retrospective descriptive study from 61 patients with advanced HCC to receive sorafenib at Military Hospital 175 from January 2022 to December 2024. Results: Median OS was 4 months [95% CI: 3.2–6.8 months]. Child-Pugh A patients had a median survival rate significantly longer than Child-Pugh B patients: 12 months vs. 6 months (p=0.003). Median PFS was 4 months [95% CI: 2.6–5.4 months], DCR was 49.2%. The most common toxicity was hand-foot syndrome (41%), of which grade 3–4 accounted for 11.5%. Conclusion: Sorafenib in the treatment of advanced HCC has a favorable disease control rate and common toxicities were grade 1-2. However, there are no significant overall survival and progression-free survival improvement. Patients with Child-Pugh B liver function had poorer OS than those with Child-Pugh A function.